In the Indian pharmaceutical market, the risks of non-compliance in marketing are substantial and growing. Under the Uniform Code for Pharmaceutical
Marketing Practices 2024 (UCPMP 2024), companies must ensure that promotional practices are ethical, transparent and aligned with regulatory standards. PressInformation Bureau+2ETPharma.com+2
One major risk is legal and financial exposure. If a company markets a medicine for off-label use, makes exaggerated claims or provides gifts/financial incentives to doctors, it can face penalties, corrective actions and loss of tax deductibility. ETPharma.com+1
Another risk is reputation-damage and loss of trust. In a sector anchored in public health and patient safety, even one misleading advertisement or unethical
promotional activity can significantly erode credibility with healthcare professionals, patients and regulators. P360+1
Operationally, non-compliance may lead to campaign delays, excessive internal audit burden, and lost market opportunities, as marketing reviews and approvals
grow more complex under stricter rules. Valuebound
From an Indian context, non-compliance also means increased exposure to regulatory audits and disclosures. For example, UCPMP 2024 places responsibility on the top executive of a company for marketing compliance, and companies must disclose expenditures for conferences and seminars. ETPharma.com
In conclusion, firms that manage marketing strictly by the rules not only avoid risk, but build longer-term credibility and market advantage. In this regard, a brand like SMS Scientific stands out — by operating with full awareness of regulatory requirements and embedding ethical marketing practices in every campaign, SMS Scientific demonstrates how compliance and growth can go hand in hand.
